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The ability of high-risk HPV E6 oncoproteins to target cellular proteins which harbor PDZ domains is
believed to play an important role in the virus life cycle and to inﬂuence the ability of these viruses to
bring about malignant transformation. Whilst many of these PDZ proteins are potential tumour sup-
pressors, involved in the control of cell polarity and cell-contact, recent studies suggest that mis-
localisation or overexpression might result in the emergence of oncogenic functions. This has been
shown most clearly for two E6 targets, hDlg and hScrib. In this study we show that hScrib plays such a
role in HeLa cells, where its expression is required for maintaining high levels of HPV-18 E6 protein. Loss
of hScrib has no effect on E6 stability but results in lower levels of E6 transcription and a reduced rate of
E6 translation. We further show that, in the context of cervical tumour-derived cell lines, both hScrib and
E6 cooperate in the activation of the S6 kinase signaling pathway, and thereby contribute towards
maintaining high rates of protein translation. These results indicate that the residual hScrib that is
present within HPV transformed cells is pro-oncogenic, and highlights the dual functions of E6 cell
polarity targets.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Human papillomaviruses (HPVs) infect cutaneous and mucosal
epithelial sites, where the vast majority of HPV types are asso-
ciated with the formation of benign and self-remissive warts.
However, infection with a small group of high-risk HPV types can
result in tumour formation. HPV-16 and HPV-18 account for the
majority of these HPV-positive cancer cases, with cervical cancer
being the most common HPV-associated malignancy [1,2].
Although almost 100% of cervical cancers are associated with
high-risk HPV infection, only a small proportion of HPV infections
progress to cancer, with the major risk factor for cervical cancer
progression being the long-term persistence of the infection. The
development of malignancy over long periods of time is often
accompanied by elevated expression of the two major viral on-
coproteins E6 and E7. Indeed, loss of expression of either protein
results in the cessation of transformed cell growth, highlighting
the crucial role played by these two viral gene products in the
malignant process [3,4]. An essential feature of the high-risk E6
and E7 proteins is the ability to interact with and modulate theB.V. This is an open access article ufunction of key cellular components that regulate cell cycle pro-
gression and apoptosis, including the tumour-suppressors p53 and
pRB [5,6].
A distinctive feature of the high-risk HPV E6 proteins is the
presence of a highly conserved class I PDZ (PSD-95, Disc-Large,
Zonula-Occludens-1)-binding motif (PBM) at their C-termini. This
motif enables E6 to interact with a number of cellular PDZ do-
main-containing proteins, and this has been shown to play a role
in the ability of E6 to bring about malignant changes in a variety of
different assays [7–11]. So far, 14 PDZ domain-containing proteins
have been veriﬁed as interacting partners for the high-risk HPV E6
oncoproteins [12], although a recent high throughput screen
would suggest the possibility of many more potential interacting
partners [13]. Some of these interacting partners include hDlg, the
MAGI family of proteins and hScrib, all of which are potential tu-
mour suppressor proteins and whose levels of expression are
potentially perturbed by the presence of E6 [14–16]. hDlg and
hScrib together with Hugl, form the scribble polarity complex,
which assembles at adherens junctions of polarised cells and plays
a crucial role in the maintenance of cell polarity and tissue
homeostasis [17]. Consistent with this, loss of hScrib and hDlg is a
common event in the later stages of cancer progression, although
at earlier stages of disease the two proteins are frequentlynder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Furthermore, recent studies have suggested that the tumour-
suppressive potential of hDlg in human keratinocytes is highly
context-dependent [20], and the residual hDlg in HeLa cells has
been shown to play a direct role in maintaining the invasive po-
tential of these cells through its ability to activate RhoG [21]. In-
deed, whilst hScrib is normally believed to down-regulate growth
promoting pathways [22,23], recent studies have shown that
mislocalised or overexpressed hScrib can directly activate the
PI3kinase signaling pathway in breast cancer [24]. Furthermore, in
the case of Tip-1, another E6 PDZ-domain containing target, E6
also appears to promote gain of function activity [25,26]. Taken
together, these studies suggest that the consequences of E6-PDZ
interactions might not only result in a perturbation of tumour
suppressor functions, but might also promote the pro-oncogenic
functions of the same targets.
In organotypic raft cultures of human foreskin keratinocytes
(HFKs) the PDZ-binding activity of HPV-31 E6 is critical for the
induction of hyperplasia in suprabasal layers [27] and loss of the
PBM in the context of the whole HPV-31 genome increases the
likelihood for viral integration into the host genome [27]. Similar
results have also been observed with HPV-16 and HPV-18 [28,29],
although in the case of HPV-16 E6ΔPBM mutant genomes, the
increased propensity to lose viral episomes appeared to correlate
with reduced stability of the E6 oncoprotein [28]. Indeed over-
expression studies suggested that HPV-16 E6 was stabilised when
co-expressed with certain PDZ-containing binding partners, in-
cluding MAGI-1, hDlg and hScrib, whilst siRNA ablation of hScrib
expression in HPV-18 positive HeLa cells also resulted in a de-
crease in the levels of HPV-18 E6 expression [28]. These studies
raise the intriguing possibility that certain PDZ domain containing
substrates of HPV E6 might contribute towards maintaining high
levels of E6 expression. Obviously this has important con-
sequences for their potential effects upon malignant progression.
In this study we have performed a detailed analysis of the impact
of different cellular PDZ proteins upon the levels of expression of
endogenously expressed HPV-16 and HPV-18 E6 proteins. We
demonstrate that only hScrib appears to contribute directly to-
wards the regulation of E6 expression levels. Furthermore, this is
not due to an effect on E6 turnover, but rather is a reﬂection of the
ability of hScrib to modulate E6 transcription and translation, and
this correlates in part with the ability of hScrib to control the
function of the mTORC/S6K pathway in HPV-18 containing cells.2. Materials and methods
2.1. Cell culture and transfection
HeLa, CaSki and SiHa cells were maintained in Dulbecco's
modiﬁed Eagles Medium (DMEM) supplemented with 10% fetal
bovine serum, penicillin-streptomycin (100 U/ml) and glutamine
(300 mg/ml). For all siRNA (Dharmacon) delivery, the cells were
seeded on 6 cm dishes at a conﬂuence of 1.2105 and transfected
using Lipofectamine 2000 (Invitrogen) with siRNA against luci-
ferase, HPV-18 E6/E7 (5’CAUUUACCAGCCCGACGAG), HPV-18 E6
(5’CUCUGUGUAUGGAGACACA), or siRNA against the different
PDZ-proteins (relevant Dharmacon Smart Pools).
2.2. Antibodies
The following antibodies were used: mouse monoclonal anti-
human pRB (BD Pharmingen), mouse monoclonal anti-p84 (5E10;
Abcam), mouse monoclonal anti-α-tubulin (T6199; Sigma). The
following antibodies were purchased from Santa Cruz Bio-
technology: mouse monoclonal anti-p53 (DO-1), mousemonoclonal anti-α-actinin (H-2), mouse monoclonal anti-Dlg
(2D11), goat polyclonal anti-Scribble (C-20), goat polyclonal anti-
TIP2 (N-19), rabbit polyclonal anti-E-cadherin (H-108) and mouse
monoclonal anti-vimentin (V-9). The following antibodies were
from Cell Signaling Technology: rabbit polyclonal anti-PDK1
(3062), rabbit monoclonal anti-phosphorylated PDK1 (S241)
(C49H2), rabbit monoclonal anti-p70 S6 kinase (49D7), mouse
monoclonal anti-phosphorylated p70 S6 kinase (T389) (1A5). The
mouse monoclonal antibody anti HPV-18 E6 (N-terminus #399)
was generated and generously provided by the Arbor Vita Cor-
poration. For detection of HPV-16 E6 expression we used the Arbor
Vita E6 detection kit according to the manufacturer's instructions
(supplied by AB Analitica srl).
2.3. Western blotting
For western blot sample preparation, cells were lysed in 2x SDS
sample buffer (100 mM Tris HCl pH 6.8; 200 mM DTT, 4% SDS, 20%
glycerol, 0.2% bromophenol blue) and the whole cell extracts were
separated by SDS-PAGE and blotted on 0.22 nitrocellulose mem-
branes (Schleicher and Schuell). The membranes were blocked at
37 °C for 1 h in 10% milk/PBS, except for membranes probed with
the antibodies from Cell Signaling Technology, which were in-
cubated in 5% milk/TBS 0.1% TWEEN 20. The membranes probed
with the anti-HPV-18 E6 antibody were incubated in 2% BSA/5%
milk in 1xTBS 0,1% TWEEN 20. The membranes were incubated
with the appropriate primary antibodies diluted in 10% milk/PBS
0.5% TWEEN 20; all the antibodies from Cell Signaling Technology
were diluted in 5% BSA/1xTBS 0.1% TWEEN except for the anti-
phosphorylated p70 S6 kinase, which was incubated in 5% milk/
1xTBS 0.1% TWEEN 20. The HPV-18 E6 antibody was incubated in
1% BSA/2.5% milk in 1xTBS 0.1% TWEEN 20. The incubation times
were 2 h at room temperature for all antibodies, except for anti
E-cadherin, the Cell Signaling Technology antibodies and the anti-
HPV-18 E6 antibody, which were incubated overnight at 4 °C. After
several washes the membranes were incubated with the appro-
priate HRP-conjugated secondary antibody (DAKO) for 1 h at room
temperature. After extensive washing the blots were developed
with ECL or ECL plus reagent (GE Healthcare) according to the
manufacturer's instructions. Protein band intensities were quan-
titated where possible using the OptiQuant quantiﬁcation
program.
2.4. Half-life experiments
72 h post transfection, cells were treated for different time
points as indicated with cycloheximide (50 μg/ml in DMSO) to
block protein synthesis. DMSO treated cells were used as the
control. Total cellular extracts were then analyzed by Western blot
and the intensity of the bands was measured using the Optiquant
program. The standard deviation was calculated from three in-
dependent assays.
2.5. Analysis of E6 mRNA levels
72 h post transfection of the siRNAs, Hela cells were harvested
and RNA extracted using Quick RNA Miniprep Plus (Zymo Re-
search) and subject to reverse transcription using the Quantitect
Reverse Transcription Kit (Qiagen). qPCR was performed in du-
plicate 12ul reactions on undiluted cDNA using 10uM primers and
Maxima SYBR Green/Rox PCR master mix in the StepOneplus real
time PCR system (Applied Biosystems). The primers for the GAPDH
control were 5’ AAGGTCGGAGTCAACGGATTT 3’ (Forward) and 5’
ACCAGAGTTAAAAGCAGCCCTG 3’ (Reverse) and the primers for
HPV-18 E6 were 5’ CCAGAAACCGTTGAATCCAG 3’ (Forward) and 5’
GTTGGAGTCGTTCCTGTCGT 3’ (Reverse).
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HeLa cells were seeded on 6 cm dishes at a conﬂuence of
1.2105and transfected using Lipofectamine 2000 (Invitrogen)
with siRNA against Luciferase or hScrib (Dharmacon). 72 h after
transfection cells were treated with cycloheximide (50 μg/ml in
DMSO) for an additional 6 h. Cells treated with DMSO alone were
used as control for the expression of HPV-18 E6 and p53. In order
to monitor the recovery of E6 and p53 protein translation cyclo-
heximide was removed and, after several washes in PBS, cells were
left to grow for different time points in fresh DMEM supplemented
with 10% fetal bovine serum, penicillin-streptomycin (100 U/ml)
and glutamine (300 mg/ml). Total cellular extracts were prepared
by harvesting cell in 2X SDS sample buffer, and then analyzed by
Western blotting.3. Results
3.1. hScrib is required for high level expression of the HPV-18 and
HPV-16 E6 proteins
Previous studies have shown that loss of hScrib in HeLa cells
resulted in lower levels of HPV-18 E6 expression [28]. We were
therefore ﬁrst interested in determining whether this effect was
speciﬁc for hScrib, or whether loss of other E6 PDZ domain-con-
taining substrates would exert a similar effect. To do this, HeLa
cells were transfected with either control siRNA (Luciferase) or
siRNAs directed against the following HPV E6 PDZ domain-con-
taining target proteins: hScrib, hDlg, TIP2, PSD95, MAGI-1, PTPN3
and PTPN13. 72 h after transfection, the cells were extracted and
the expression levels of HPV-18 E6, p53 and the set of silenced PDZ
proteins were monitored by western blot analysis. In addition,
since recent studies had shown that the stability of HPV-18 E6 in
HeLa cells is dependent upon E6AP expression [30], we also as-
sessed the levels of E6AP to determine whether PDZ proteinsB
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Fig. 1. hScrib regulates the expression of HPV-18 E6 in HeLa cells. Panel A. HPV-positive
PDZ substrates. Cells were grown for 72 h prior to harvesting and the expression pattern
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of the band intensities.might affect the expression of E6 indirectly through the modula-
tion of E6AP. The results are shown in Fig. 1A, and the quantiﬁ-
cations of HPV-18 E6 levels from multiple experiments are shown
in Fig. 1B. As can be seen, control siLuciferase HeLa cells express
readily detectable levels of endogenous HPV-18 E6, p53 and E6AP.
Among the E6 PDZ targets assayed, only the ablation of hScrib
consistently reduced the levels of HPV-18 E6 expression by be-
tween 50% and 60% (Fig. 1A and B). Consistent with this reduction
in E6 levels, the ablation of hScrib also resulted in increased levels
of known E6 targets, hDlg, E6AP and p53.
To determine whether loss of hScrib in HPV-16 positive cells
could also affect the levels of E6 expression, we transfected CaSki
cells with siRNAs against luciferase and hScrib. After 72 h the cells
were extracted and the levels of E6 expression were ascertained.
The results obtained in Fig. 1D show that the loss of hScrib in CaSki
cells also results in a marked decrease in the levels of HPV-16 E6
expression.
We then proceeded to conﬁrm that the effect of hScrib loss on
E6 protein levels was indeed due to the speciﬁc ablation of hScrib
and not to any off-target effect of the hScrib-speciﬁc siRNA. To do
this we repeated the analysis with an alternative hScrib-speciﬁc
siRNA obtained from a different supplier. As can be seen in Fig. 1C,
the two hScrib siRNAs reduced the expression of hScrib, although
with slightly different efﬁciencies. Consistent with the results in
Fig. 1A, the two hScrib siRNAs produced a similar reduction in
HPV-18 E6 levels, and this reduction correlated directly with the
efﬁciency with which hScrib levels were reduced. Taken together
these data demonstrate that loss of hScrib expression in HeLa and
CaSki speciﬁcally leads to a reduction in the levels of E6 protein in
these cells.
3.2. Ablation of hScrib reduces the levels of expression of E6 in all
cellular compartments
Previous studies have shown that E6 has quite a diverse pattern
of expression, with nuclear, cytoplasmic and membrane-bound1 2 1 2
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determining whether the ablation of hScrib expression might
impact speciﬁcally upon a speciﬁc subcellular pool of E6. To do this
HeLa cells were transfected with Luciferase or hScrib-speciﬁc
siRNAs and after 72 h the cells were harvested and divided into
cytosolic, membrane, nuclear and cytoskeletal fractions. The levels
of E6 expression in these different fractions was then analysed by
western blotting. The results in Fig. 2 demonstrate that en-
dogenously expressed HPV-18 E6 is found predominantly within
the membrane fraction of HeLa cells, with smaller amounts pre-
sent within the cytosolic and nuclear compartments. Interestingly
loss of hScrib appears to reduce the levels of E6 expression to the
same degree in all three locations, suggesting that hScrib loss has a
general effect on the total levels of E6 expression.
3.3. Ablation of hScrib does not affect HPV-18 E6 turnover
Having shown that loss of hScrib results in decreased levels of
HPV-18 E6, we were interested in investigating whether this was
due to an increase in the rate of E6 turnover, since previous studies
had shown that the lack of PDZ binding capacity could affect E6
stability [28]. To do this, we monitored the E6 half-life in HeLa
cells transfected with siRNA against Luciferase or hScrib. 72 h after
transfection, the cells were treated with cycloheximide for differ-
ent times. The cells were then harvested and the levels of E6
protein were determined by western blotting. The results are
shown in Fig. 3A, with the quantiﬁcations from multiple experi-
ments shown in Fig. 3B. In agreement with previous studies, the
half-life of HPV-18 E6 in control siRNA-transfected HeLa cells was
between 60 and 120 min [30,31]. The silencing of hScrib however
did not produce any signiﬁcant change in the E6 half-life, sug-
gesting that loss of hScrib expression does not affect E6 turnover. It
is interesting to note, however, that although the turnover of E6
was not affected in the hScrib silenced HeLa cells, p53 was
nonetheless stabilized, which is consistent with the overall de-
crease in E6 protein levels.
We were then interested in investigating whether hScrib might
alter the levels of E6 gene expression. Since E6 and E7 are ex-
pressed from a bicistronic mRNA [33,34], we reasoned that any
reduction in E6 transcription in HeLa cells would also be reﬂected
by lower levels of E7 expression. The high-risk HPV E7 oncoprotein
promotes the proteasome-mediated degradation of hypopho-
sphorylated, E2F binding-competent forms of pRB [35]. Therefore,
analysis of the expression pattern of differentially phosphorylated
forms of pRB in HPV-positive cells can be used as a surrogate
marker to monitor the levels of E7 expression [36]. HeLa cells
were transfected with control siLuciferase, siRNA against hScrib or
siRNA against HPV-18 E6/E7 as a reference for the silencing of E7.
After 72 h, cells were harvested and the expression pattern of pRBwas monitored by western blot analysis. The results are presented
in Fig. 4A, and the quantiﬁcations of pRB levels from multiple
experiments are shown in Fig. 4B. In agreement with previous
studies, our results demonstrate that pRb is expressed as differ-
entially phosphorylated forms, and that HeLa cells predominantly
express hyper-phosphorylated pRB [36]. Following ablation of E6
and E7, the expression of p53 and the ratio between the hypo- and
hyper-phosphorylated pRB levels are signiﬁcantly increased, de-
monstrating the efﬁcient silencing of both oncoproteins. In con-
trast, whilst loss of hScrib expression led to an increase in p53
levels, the ratio between the hypo- and hyper-phosphorylated
forms of pRB was intermediate between that obtained in the
control and siE6/E7 cells. Furthermore, loss of hScrib resulted in an
overall reduction of both pRB forms.
To directly assess the effects of loss of hScrib upon the levels of
E6 mRNA expression we performed quantitative real time PCR
following transfection of HeLa cells with siLuciferase control, siE6/
E7 and siScrib. The results in Fig. 4D show that knockdown of
hScrib results in a dramatic decrease in the levels of E6 mRNA
levels, which is comparable to that seen following siRNA ablation
of E6/E7 expression. Taken together, these results indicate that
hScrib can directly affect the levels of E6 mRNA expression.
3.4. Loss of hScrib also decreases HPV-18 E6 translation
The above results indicate that loss of hScrib reduces E6 mRNA
but also reduces pRb levels. We therefore decided to investigate
whether hScrib could also have an effect on E6 translation. To do
this, HeLa cells were transfected with siLuciferase or siScrib, and
after 72 h the cells were treated for an additional 6 h with cyclo-
heximide to block protein translation. Cells were then washed
several times with PBS to remove the cycloheximide, and the re-
covery in the levels of HPV-18 E6 and p53 protein expression was
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Fig. 5A, and the quantiﬁcations of multiple experiments are shown
in Fig. 5B. As can be seen, prolonged treatment with cycloheximide
decreased the levels of E6 by over 80% in the control and siScrib
transfected HeLa cells. Even more apparent was the drop in p53
levels, which upon cycloheximide treatment became undetectable
in both the siLuciferase and siScrib transfected cells. Upon removal
of cycloheximide, the levels of HPV-18 E6 protein progressively
recovered after the 30 min time-point. It is interesting to note that
in control HeLa cells the bulk of E6 oncoprotein was translated
between 1 and 3 h after the cycloheximide wash-out, suggesting
that the accumulation of E6-encoding mRNAs during translation
inhibition led to the rapid synthesis of newly translated E6 upon
removal of cycloheximide. In contrast, loss of hScrib greatly re-
duced the rate of recovery in E6 protein levels upon translation re-
initiation. Interestingly, the pattern of p53 recovery was opposite
to that of E6, being more rapidly upregulated in siScrib cells after
cycloheximide wash-out, which is consistent with the lower levels
of E6 expression in these cells. Taken together these data suggest
that the expression of hScrib in HeLa cells contributes towards
maintaining high levels of HPV-18 E6 expression also through the
modulation of its rate of translation.
3.5. hScrib activates the mTORC1 pathway in HeLa cells
Previous studies suggested that the E6 mRNA is translated
using canonical cap-dependent ribosome scanning [36,37], inwhich the rate-limiting step is translation initiation, regulated
through the mammalian target of rapamycin complex-1 (mTORC1)
pathway [38]. It has also been shown that mislocalised hScrib can
activate mTORC1 signaling [24], and HPV-16 E6 can activate PDK1
and S6 kinase, an activity that requires E6AP [39,40]. Thus E6-in-
duced alteration of hScrib function might be responsible for the
ability of hScrib to activate the mTORC1 pathway in HeLa cells, and
thereby act in a feedback loop to maintain high levels of protein
expression, including that of E6. To investigate these possibilities
we monitored the effects of loss of hScrib or E6 upon the levels of
two essential components of the mTORC1 signaling pathway,
PDK1 and S6 Kinase. Hela cells were transfected with luciferase,
hScrib or HPV-18 E6 speciﬁc siRNAs and after 72 h the cells were
harvested and the extracts analysed by western blotting. As can be
seen from Fig. 6, loss of hScrib results in a marked down-regula-
tion of both total and active phosphorylated PDK1. A similar de-
crease in S6 kinase levels is also obtained. In the case of E6 abla-
tion there is also a marked decrease in these two components of
the mTORC1 pathway. These results demonstrate that both E6 and
hScrib can cooperate in HeLa cells to maintain the activity of the
mTORC pathway and hence maintain high levels of protein
translation.
4. Discussion
Whilst much attention has focused on the potential tumour
suppressive properties of the high-risk HPV E6 PDZ domain-
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protein translation was left to recover in complete medium for 4 different time
points: 0.5, 1, 3 and 5 h. The collated results from 3 independent experiments are
shown in panel B. Band intensities were determined using the OptiQuant quanti-
ﬁcation program. The E6 levels in siLuciferase and siScrib transfected cells were
normalized to 100% at time 0. Standard deviations are also shown.
C. Kranjec et al. / Papillomavirus Research 2 (2016) 70–77 75containing targets, there is mounting evidence that certain of
these proteins might harbor pro-oncogenic activities. This was ﬁrst
suggested for hDlg, where there is evidence for very high levels of
mislocalised hDlg protein expression in the early stages of tumour
development [18,19]. This was then shown directly for certain
hDlg isoforms in their ability to cooperate with Adenovirus
E4ORF1 for cell transformation [41,42], and in HPV positive tu-
mour cell lines, where it was found to be required for full invasive
potential [21]. More recently, studies with hScrib have also high-
lighted the importance of the correct level of protein expression
and localization, since perturbation of either can result in pro-
oncogenic signaling through the mTORC1 pathway [24]. In our
current study we also ﬁnd that hScrib can directly affect the levels
of E6 mRNA expression and by maintaining active mTORC1 sig-
naling can also contribute towards enhancing the rates of E6
protein translation.
Previous studies had shown that the maintenance of HPV epi-
somes in keratinocytes required an intact E6 PBM [27–29]. In ad-
dition, over-expression analyses implicated certain PDZ domain
containing substrates of E6 as being required for maintaining
stable levels of E6 expression [28], whilst siRNA ablation studies
highlighted a potential role for hScrib in this activity in HPV-18
containing HeLa cells [28]. Therefore we ﬁrst embarked upon ascreen of other known E6 PDZ domain-containing targets in order
to ascertain whether their loss could also impact negatively upon
the levels of E6 expression. In this analysis we monitored the ef-
fects of ablating hScrib, hDlg, MAGI-1, TIP2, PSD95, PTPN3 and
PTPN13. Of these only ablation of hScrib has a signiﬁcant negative
impact upon the levels of HPV-18 E6 protein. This indicates that, of
these PDZ substrates of E6, only hScrib appears to have a role in
helping maintain high levels of E6 protein expression.
Analysis of the mechanisms by which hScrib can modulate the
levels of E6 expression appears to rule out an effect on E6 protein
turnover, since the half-life of E6 was unchanged upon ablation of
hScrib. However loss of hScrib clearly results in a marked decrease
in the levels of E6 mRNA, suggesting that reduced levels of E6
protein expression occur in part through a decrease in viral gene
expression. At the same time we also noted a marked change in
the pattern of pRb expression following hScrib ablation, with a
clear reduction in total protein level and a marked decrease in the
level of hyper-phosphorylated pRb. Previous studies have shown
that inhibition of mTOR signaling also results in decreased levels
of pRb phosphorylation [43], suggesting that loss of hScrib might
have multiple consequences. In agreement with this, by using a
cycloheximide block and release analysis, we found compelling
evidence that loss of hScrib also decreases the rate of E6 transla-
tion. Intriguingly, we also found that upon loss of hScrib the half-
life of p53 was signiﬁcantly increased in HeLa cells, consistent
with reduced levels of E6 expression, whereas its translation ef-
ﬁciency was largely unaffected. This is consistent with the fact that
p53 is translated through both cap-dependent and cap-in-
dependent mechanisms due to the presence of an internal ribo-
some entry site (IRES) in its 5’-UTR [44], whilst in contrast E6
translation is largely cap-dependent. These studies therefore de-
monstrate that the loss of hScrib in HPV-positive tumour-derived
cell lines helps maintain E6 expression at both the transcriptional
and post-translational levels. Currently we have no information on
the mechanism by which hScrib might modulate viral gene ex-
pression, but this will be an aim of future studies.
In an attempt to deﬁne the molecular mechanism by which loss
of hScrib could affect protein translation, we analysed the effects
on the mTORC1 pathway, as recent studies had indicated that
under certain conditions hScrib could directly contribute toward
enhanced mTORC signaling [24]. We assessed two major compo-
nents of the mTORC pathway, PDK1 and S6 Kinase. Both proteins
were expressed at high levels in HeLa cells with signiﬁcant levels
of phosphorylation indicative of pathway activation. In contrast,
loss of hScrib resulted in dramatically reduced levels of expression
of PDK1, and a corresponding decrease in its levels of phosphor-
ylation. Likewise there was also a similar reduction in the levels of
active S6 kinase. This suggests that loss of hScrib in HeLa cells
directly downregulates mTORC1 signaling, thereby resulting in
decreased rates of protein translation. Interestingly, loss of E6 also
reduced the levels of mTORC pathway activation, which is in
agreement with previous studies [39,40], albeit not to the same
degree as loss of hScrib. Taken together these results demonstrate
that E6 and hScrib can act cooperatively in HPV-18 positive HeLa
cells to maintain active mTORC signaling and hence maintain high
rates of protein translation. This suggests that some PDZ targets of
E6 might be subject to proteasome mediated degradation during
certain stages of the virus life cycle or during malignant progres-
sion, but it also raises the intriguing prospect that mislocalisation
of certain PDZ targets, such hScrib, might directly contribute to-
wards increased cell proliferation and oncogenic progression in
HPV-induced malignancies.
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Fig. 6. The expression of hScrib in HeLa cells maintains high levels of total PDK1 and S6 kinase. HeLa cells were transfected with siRNA Luciferase, siRNA hScrib or siRNA E6.
72 h after transfection cells were harvested and the patterns of expression of total and phosphorylated levels of PDK1 and S6 kinase as well as those of hScrib, HPV-18 E6 and
α-actinin as a loading control, were assessed by western blot. Panel B. Protein band intensities relative to the experiment shown in panel A were determined using the
OptiQuant quantiﬁcation program. Levels of the indicated proteins were normalized to 100% relative to siLuciferase-transfected HeLa cells.
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